DE60237841D1 - Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung - Google Patents

Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung

Info

Publication number
DE60237841D1
DE60237841D1 DE60237841T DE60237841T DE60237841D1 DE 60237841 D1 DE60237841 D1 DE 60237841D1 DE 60237841 T DE60237841 T DE 60237841T DE 60237841 T DE60237841 T DE 60237841T DE 60237841 D1 DE60237841 D1 DE 60237841D1
Authority
DE
Germany
Prior art keywords
trail
formulations
compositions based
apo2 ligand
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237841T
Other languages
English (en)
Inventor
Heather Flores
Tanya P Lin
Roger Pai
Timothy C Matthews
Zahra Shahrokh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE60237841D1 publication Critical patent/DE60237841D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DE60237841T 2001-11-13 2002-11-12 Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung Expired - Lifetime DE60237841D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33824901P 2001-11-13 2001-11-13
PCT/US2002/036251 WO2003042344A2 (en) 2001-11-13 2002-11-12 Apo2 ligand/trail formulations

Publications (1)

Publication Number Publication Date
DE60237841D1 true DE60237841D1 (de) 2010-11-11

Family

ID=23324037

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237841T Expired - Lifetime DE60237841D1 (de) 2001-11-13 2002-11-12 Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung

Country Status (11)

Country Link
US (3) US7741282B2 (de)
EP (3) EP2322165A1 (de)
JP (2) JP2005521640A (de)
AT (1) ATE482716T1 (de)
CA (1) CA2466054C (de)
DE (1) DE60237841D1 (de)
DK (1) DK1450847T3 (de)
ES (1) ES2351786T3 (de)
IL (3) IL161812A0 (de)
PT (1) PT1450847E (de)
WO (1) WO2003042344A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01013236A (es) * 1999-06-28 2002-06-21 Genentech Inc Metodos para hacer ligando apo-2 mediante el uso de iones metalicos divalentes.
US7741285B2 (en) * 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
JP2006523609A (ja) * 2002-12-31 2006-10-19 アルタス ファーマシューティカルズ インコーポレイテッド タンパク質結晶およびイオン性ポリマーの複合体
MXPA05007181A (es) 2002-12-31 2006-04-07 Altus Pharmaceuticals Inc Cristales de la hormona de crecimiento humano y metodos para prepararlos.
US20060019234A1 (en) * 2004-07-22 2006-01-26 Shanbrom Technologies, Llc Modern blood banking employing improved cell preservation composition
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
US20090155247A1 (en) * 2005-02-18 2009-06-18 Ashkenazi Avi J Methods of Using Death Receptor Agonists and EGFR Inhibitors
JP2008542430A (ja) * 2005-06-06 2008-11-27 ノボ・ノルデイスク・エー／エス 安定化ｉｌ−２１組成物
PT1915626E (pt) * 2005-08-16 2012-02-03 Genentech Inc Sensibilidade da apoptose a apo2l/trail por ensaio de expressão de galnac-t14 em células/tecidos
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
CN101584858A (zh) 2005-12-20 2009-11-25 布里斯托尔-迈尔斯斯奎布公司 稳定蛋白质制剂
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
DK2190473T3 (da) 2007-08-15 2013-03-25 Circassia Ltd Peptid med reduceret dimerdannelse
WO2009040811A2 (en) * 2007-09-24 2009-04-02 Bar-Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
EP2111871A1 (de) * 2008-04-26 2009-10-28 Sandoz AG Stabilisierte Flüssigformulierung
EP2350271B1 (de) 2008-11-20 2016-01-27 Biogen MA Inc. Arginin-inaktivierung von umhüllten viren
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
DE102008064553B4 (de) * 2008-12-22 2015-05-13 Technische Universität Dresden Verfahren zum Nachweis und/oder zur Identifizierung hormonell wirksamer Substanzen
US8293100B2 (en) 2009-03-13 2012-10-23 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
SG181496A1 (en) 2009-12-18 2012-07-30 Csl Ltd Method of purifying polypeptides
RU2739078C2 (ru) * 2010-04-27 2020-12-21 ЭсСиАйЭл Текнолоджи ГмбХ Стабильные водные композиции белка MIA/CD-RAP
JP2013525484A (ja) * 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
CA2834776A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
WO2013167720A1 (en) * 2012-05-11 2013-11-14 Novartis Ag Crystallization methods for purification of monoclonal antibodies
WO2014199373A1 (en) * 2013-06-09 2014-12-18 Efranat Ltd. Compositions comprising gc- macrophage activating factor and uses thereof
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS5829958B2 (ja) * 1977-03-07 1983-06-25 工業技術院長 タンパク質結晶の形成方法
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
JPS60126084A (ja) * 1983-12-13 1985-07-05 Toyo Jozo Co Ltd グリセロリン酸オキシダーゼの安定化法
JPS62283932A (ja) 1986-05-29 1987-12-09 Green Cross Corp:The 組織プラスミノ−ゲンアクチベ−タの乾燥製剤
ES2032831T5 (es) 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
JP2602850B2 (ja) * 1987-10-27 1997-04-23 富士通株式会社 単結晶作製方法
US5169770A (en) 1987-12-21 1992-12-08 The University Of Toledo Agrobacterium mediated transformation of germinating plant seeds
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
CH682806A5 (de) 1992-02-21 1993-11-30 Medimpex Ets Injektionsgerät.
JP3007785B2 (ja) * 1993-03-16 2000-02-07 旭化成工業株式会社 トロンボモジュリン組成物およびその変性防止方法
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
ES2253753T3 (es) * 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
KR20050004269A (ko) 1996-10-25 2005-01-12 휴먼 게놈 사이언시즈, 인코포레이티드 뉴트로킨 알파
AU713473B2 (en) 1996-12-23 1999-12-02 Immunex Corporation Receptor activator of NF-kappa B, receptor is member of TNF receptor superfamily
US6342363B1 (en) 1997-01-28 2002-01-29 Human Genome Sciences, Inc. Death domain containing receptor 4 nucleic acids and methods
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
WO1998041629A2 (en) 1997-03-17 1998-09-24 Human Genome Sciences, Inc. Death domain containing receptor 5
US6140475A (en) * 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
RO128635A2 (ro) 1997-04-16 2013-07-30 Amgen Inc. Anticorp sau fragment al acestuia care se leagă la opgbp şi utilizarea acestuia, utilizarea unei forme solubile de odar, şi metodă de identificare a unui compus care descreşte activitatea opgbp
AU7126498A (en) 1997-04-16 1998-11-11 Millennium Pharmaceuticals, Inc. Tumor necrosis factor receptor related proteins tango-63d and tango-63e
EP1860187B1 (de) 1997-05-15 2011-07-13 Genentech, Inc. Apo-2-Rezeptor
EP2083079A1 (de) 1997-06-18 2009-07-29 Genentech, Inc. Apo-2DcR
JP2002507893A (ja) 1997-07-02 2002-03-12 ザ プロクター アンド ギャンブル カンパニー 食品に制御された量の成分を添加するための懸濁液
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
WO1999006673A1 (en) 1997-07-30 1999-02-11 Eg & G Sealol, Inc. Improved brush seal and method of making same
EP1003864A1 (de) 1997-08-15 2000-05-31 Idun Pharmaceuticals, Inc. Trail rezeptoren, für diese kodierende nukleinsäure, und verfahren zu deren verwendung
AU8485098A (en) 1997-08-26 1999-03-16 Genentech Inc. Rtd receptor
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
EP1045906B1 (de) 1998-01-15 2008-10-15 Genentech, Inc. Apo-2 ligand
JP4194681B2 (ja) * 1998-01-20 2008-12-10 太陽化学株式会社 可溶性γ−リベチン複合体の製造法
AU765003B2 (en) 1998-03-27 2003-09-04 Genentech Inc. Apo-2 ligand-anti-her-2 antibody synergism
GB2349636A (en) 1998-09-17 2000-11-08 Adv Liquid Packaging Corp Resealable can
FR2783596B1 (fr) 1998-09-23 2001-03-09 Eurokera Ensemble prefabrique destine a la realisation de tables de cuisson
EP1192185B1 (de) 1999-06-09 2006-06-21 Genentech, Inc. Apo-2l rezeptor-agonist und cpt-11 synergie-effekt
MXPA01013236A (es) 1999-06-28 2002-06-21 Genentech Inc Metodos para hacer ligando apo-2 mediante el uso de iones metalicos divalentes.
AUPQ312699A0 (en) 1999-09-28 1999-10-21 Electrical Moulded Components Pacific Pty Ltd Electrical reticulation apparatus
AU766984B2 (en) 1999-09-30 2003-10-30 Trustees Of The University Of Pennsylvania, The Trail: an inhibitor of autoimmune inflammation and cell cycle progression
EP1220682B1 (de) 1999-10-04 2006-11-22 Novartis Vaccines and Diagnostics, Inc. Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend polypeptide
ATE269716T1 (de) * 2000-02-29 2004-07-15 Pfizer Prod Inc Stabilisierter granulozyten-kolonie- stimulierender faktor
CA2415473A1 (en) 2000-07-27 2002-02-07 Genentech, Inc. Apo-2l receptor agonist and cpt-11 synergism
WO2003029420A2 (en) * 2001-10-02 2003-04-10 Genentech, Inc. Apo-2 ligand variants and uses thereof
US7741285B2 (en) * 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations

Also Published As

Publication number Publication date
IL161812A (en) 2013-02-28
JP5042959B2 (ja) 2012-10-03
IL161812A0 (en) 2005-11-20
ES2351786T3 (es) 2011-02-10
ATE482716T1 (de) 2010-10-15
EP2322165A1 (de) 2011-05-18
WO2003042344A3 (en) 2003-11-27
WO2003042344A2 (en) 2003-05-22
US7741282B2 (en) 2010-06-22
JP2009108040A (ja) 2009-05-21
US8470969B2 (en) 2013-06-25
US20050020498A1 (en) 2005-01-27
EP1450847A4 (de) 2007-08-29
DK1450847T3 (da) 2010-12-13
CA2466054A1 (en) 2003-05-22
EP2332531A1 (de) 2011-06-15
JP2005521640A (ja) 2005-07-21
US20110269947A1 (en) 2011-11-03
US20050080006A1 (en) 2005-04-14
PT1450847E (pt) 2011-01-05
EP1450847B1 (de) 2010-09-29
CA2466054C (en) 2012-01-03
IL197705A0 (en) 2009-12-24
EP1450847A2 (de) 2004-09-01
EP2332531B1 (de) 2019-07-10

Similar Documents

Publication Publication Date Title
DE60237841D1 (de) Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung
DE60236600D1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
ATE517089T1 (de) Trifluormethylsubstituierte spirocyclische ketoenole und ihre verwendung als schädlingsbekämpfungsmittel und herbizide
ECSP045255A (es) Cumarinas utiles como biomarcadores
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
CA2492096A1 (en) Cis-alkoxy-substituted spirocyclic 1-h-pyrrolidine-2,4-dione derivatives serving as pesticides
EP1649006A4 (de) Exo-spezifische amylase-polypeptide, diese polypeptide codierende nukleinsäuren und verwendungen davon
ATE466012T1 (de) Pyrazolo 3,4-b pyridinverbindungen und ihre verwendung als phosphodiesterase inhibitoren
MXPA03008754A (es) Derivados de piridina fundidos para utilizarse como agonistas receptores vaniloide para tratar dolor.
DE602004029503D1 (de) Plasmid der 2-mikron-familie und verwendung davon
DE60042066D1 (de) Chimärische dr4 antikörper und ihre verwendung
DE60142828D1 (de) Modifizierte oligonukleotide zur unterscheidung von fehlpaarungen
DK1419163T5 (da) Tricykliske imidazopyridiner
WO2005035537A3 (en) Substituted tricyclic heterocycles and their uses
TW200716130A (en) Purified form of tanaproget
MXPA06000038A (es) Pirimidinas 2-sustituidas.
ATE240326T1 (de) Pyrrolo-(3,2-b)pyridine und ihre verwendung als 5-ht1f agonisten
WO2000043375A3 (de) Substituierte arylheterocyclen
DE602004030231D1 (de) Pyrimidinonverbindungen als calcilytica
AU2003259750A1 (en) Methods and compositions for targeting secretory lysosomes
ATE437846T1 (de) Cyclooct-(en-)yl-derivate zur verwendung als duftstoffe
ATE389014T1 (de) Phosphorylierte glyoxalase i und deren verwendung
DE60311000D1 (de) Indolderivate und deren verwendung als 5-ht liganden
DE69706441D1 (de) Tetracyclische aromatische retinoide verbindungen, ihre herstellung und verwendung
DE602005005015D1 (de) Bicycloä3.3.1ünonane und bicycloä3.3.ü nonene und deren verwendung als geschmack- oder duftstoffe